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ferrite nanocomplex-based MRI contrast agents
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Abstract 
Background: Cardiovascular diseases are the most prevalent cause of morbidity and mortality affecting millions of 
people globally. The most effective way to counter cardiovascular complications is early diagnosis and the safest non-
invasive diagnostic approach is magnetic resonance imaging (MRI). In this study, superparamagnetic ferrite nanoparticles 
doped with zinc, exhibiting highly enhanced saturation magnetization and T2 and computed tomography (CT) contrast 
were synthesized. These nanoparticles have been strategically engineered using bovine lactoferrin (Lf ), polyethylene 
glycol (PEG), and heat shock protein (Hsp)-70 antibody specifically targeting atherosclerosis with potential therapeutic 
value. The nanocomplexes were further validated in vitro to assess their cytotoxicity, internalization efficiency, effects on 
cellular proliferation and were assessed for MRI as well as X-ray CT in ex vivo Psammomys obesus rat model.
Results: Optimized zinc doped ferrite nanoparticles (Zn0.4Fe2.6O4) with enhanced value of maximum saturation 
magnetization value on 108.4 emu/g and an average diameter of 24 ± 2 nm were successfully synthesized. Success-
fully incorporation with bovine lactoferrin, PEG and Hsp-70 (70 kDa) antibody led to synthesis of spherical nanocom-
plexes (size 224.8 nm, PDI 0.398). A significantly higher enhancement in T2 (p < 0.05, 1.22-fold) and slightly higher T1 
(1.09-fold) and CT (1.08-fold) contrast compared to commercial ferrite nanoparticles was observed. The nanocom-
plexes exhibited effective cellular internalization within 2 h in both THP-1 and Jurkat cells. MRI scans of contrast agent 
injected animal revealed significant arterial narrowing and a significantly higher T2 (p < 0.05, 1.71-fold) contrast in 
adult animals when compared to juvenile and control animals. The excised heart and aorta agar phantoms exhibited 
weak MRI contrast enhancement in juvenile animal but significant contrast enhancement in adult animal specifically 
at the aortic arch, descending thoracic aorta and iliac bifurcation region with X-ray CT scan. Histological investiga-
tion of the contrast agent injected aorta and heart confirmed site target-specific accumulation at the atheroscle-
rotic aortic arch and descending thoracic aorta of the adult animal with severely damaged intima full of ruptured 
microatheromas.
Conclusion: Overall, the study demonstrates the strategic development of nanocomplex based bimodal MRI and CT 
contrast agents and its validation on Psammomys obesus for atherosclerosis diagnostics.
Keywords: Atherosclerosis, Zinc doped ferrite nanoparticles, Heat shock protein, Lactoferrin, Psammomys obesus, 
Magnetic resonance imaging
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Background
Atherosclerosis is a root cause of cardiovascular diseases 
(CVD) leading to morbidity and mortality in millions 
of people worldwide [1, 2] and is often symptomatically 
silent until the occurrence of a catastrophic clinical event 
such as myocardial infarction, stroke or peripheral vascu-
lar diseases. The most reliable and conventional invasive 
technique for the visualization of affected blood vessels, 
either arteries or veins is catheter angiography [3] which 
is highly invasive, requires a complicated operative proce-
dure, exposes the patient to X-ray radiation, is time con-
suming and the catheter may injure the artery which may 
lead to internal bleeding. On the other hand, magnetic 
resonance imaging (MRI) is a non-invasive, painless, 
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and safe diagnostic technology that uses a magnetic field 
and radio frequency to produce a detailed image of the 
body’s organs and structures with high spatial resolu-
tion depending on the differences in longitudinal (T1) 
and transverse (T2) proton relaxation times of contrast 
agents that can effectively improve the MRI contrast 
between normal and diseased tissues [4]. Paramagnetic 
gadolinium chelates are the most widely used commer-
cial MRI contrast agents used for MRI based diagnostics 
[5]. However, Gadolinium exhibits high in  vivo toxicity 
and therefore must be modified with organic chelators 
such as diethylene triamine pentaacetic acid (Gd-DTPA) 
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (Gd-DOTA) [6]. Even after chelation gadolinium 
based contrast agents exhibit nephrogenic fibrosing der-
mopathy [7] and nephrogenic systemic fibrosis [8] in 
patients with renal insufficiency, primarily due to com-
petitive transmettalation of divalent or trivalent cations 
with gadolinium [7, 9].
Engineered nanoparticulate contrast agents progres-
sively contribute to the field of cardiovascular diagnostics 
and molecular imaging by providing several advantages 
over traditional imaging contrast agents [10, 11]. The 
most extensively studied class of magnetic nanoparticles 
for contrast agents development are iron oxide nanopar-
ticles, also referred as ferrite nanoparticles. This is due to 
their superparamagnetic nature, biodegradability, inoffen-
sive toxicity profile, low particle dimensions, high surface 
to volume ratio and reactive surface readily modifiable 
with biocompatible coatings, targeting/therapeutic mol-
ecules as well as other imaging modalities [4, 12–15]. The 
mode of action of ferrite nanoparticles is by enhancing 
the relaxation rate or shortening the T2 relaxation time by 
increasing field inhomogeneity of surrounding protons to 
creating strong negative MRI contrast [4, 12–15]. Ferrite 
nanoparticles can be doped with zinc, a micronutrient to 
considerably enhance the saturation magnetization (MS) 
for improved MRI contrast while effectively reducing the 
chances of iron overloading by iron cation replacement 
[16, 17]. Zinc is the most suitable candidate as a dopant 
as Food and Drug Administration (FDA) recommends a 
high reference daily value (DV) for zinc and iron to be 15 
and 18 mg respectively, considerably much more than the 
values for other possible dopants, for example manganese 
and cobalt at 2 mg (http://www.fda.gov).
In the present study, we developed and validated highly 
superparamagnetic zinc doped ferrite (ZF) nanoparti-
cle based nanocomplexes with minimized in  vivo toxic-
ity compared to commercial ferrite based MRI contrast 
agents. Three types of bovine lactoferrin-zinc ferrite (Lf-
ZF) nanocomplexes were developed, Hsp-70 targeted 
lactoferrin embedded ZF nanoparticles (Hsp-70 Lf-ZF), 
Hsp-70 targeted chitosan encapsulated lactoferrin 
embedded ZF nanoparticles (Hsp-70 Ch-Lf-ZF) and 
Hsp-70 targeted polyethylene glycol assisted lactoferrin 
embedded ZF (Hsp-70 Lf-PEG-ZF). Lf-ZF forms the core 
of all nanocomplexes, where superparamagnetic ZF nan-
oparticles generate MRI contrast and lactoferrin acts as a 
targeting and therapeutic protein against atherosclerosis. 
Lactoferrin is a naturally available protein with anti-bac-
terial, anti-viral, anti-inflammatory and anti-carcinogenic 
properties and also helps in boosting the immune sys-
tem by activation of T lymphocytes [18, 19]. Since, the 
temporal expression of  Hsps’ has been demonstrated at 
atherosclerotic lesion [20], this is the first attempt dem-
onstrating Hsp-70 targeted approach for atherosclerosis 
diagnostics. Validation of the developed nanocomplex 
contrast agent was performed with Psammomys obesus 
(P. obesus), a polygenic animal model for type-2 diabetes, 
obesity and atherosclerosis [21, 22].
Results and discussion
Characterization of zinc doped ferrite based 
nanocomplexes
The first phase of this study was the synthesis, charac-
terization and optimization of zinc-doped ferrite nano-
particles (ZF) with their physicochemical properties as 
the primary criteria in order to procure a highly effec-
tive MRI contrast. Selection of zinc, a micronutrient, as 
the dopant was  implemented as a strategy to maximize 
the characteristic magnetic property of the nanoparti-
cles and simultaneously minimizing potential cytotoxic-
ity in vivo at higher concentrations. Zinc doping reduces 
the chances of iron overloading by crystallographic fer-
rite iron cation replacement with highly enhanced satura-
tion magnetization of 108.4 emu/g at room temperature 
(data not shown), considerably higher than conventional 
ferrite nanoparticles employed for MRI contrast agent 
development. Transmission electron microscopy  (TEM) 
revealed the formation of ZF nanoparticles with an aver-
age diameter of 24 ± 2 nm (Fig. 1a) and X-ray diffractom-
etry (XRD) confirmed the formation of crystallographic 
spinel structure (Fig.  1b). The next phase of the study 
involved the design and development of atherosclerosis-
specific nanocomplex MRI contrast agents with empha-
sis on their in  vitro validation by cellular proliferation, 
toxicity, internalization and molecular targeting assess-
ment. To achieve this goal, three spherical nanosized 
complexes based on different combinations of ZF nano-
particles, bovine lactoferrin, chitosan and PEG were 
developed. All nanocomplexes were equipped with heat 
shock protein (Hsp)-70 antibodies for effective targeting 
of the atherosclerotic inflammatory site. The three types 
of engineered nanocomplexes developed were named 
according to their constituents: Hsp-70 targeted lactofer-
rin embedded ZF nanoparticles (Hsp-70 Lf-ZF), Hsp-70 
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targeted chitosan encapsulated lactoferrin embedded 
zinc ferrite nanoparticles (Hsp-70 Ch-Lf-ZF) and Hsp-70 
targeted polyethylene glycol assisted lactoferrin embed-
ded ZF nanoparticles (Hsp-70 Lf-PEG-ZF). Lactoferrin 
is also a known iron modulator internalized by vari-
ous cells such as mucosal epithelial cells, hepatocytes, 
monocytes, macrophages, polymorphonuclear leuko-
cytes, lymphocytes, thrombocytes and fibroblasts due to 
the presence of a number of cellular receptors including 
transferrin receptors, Lactoferrin receptors and Lipo-
protein receptor-related proteins [18, 23–25]. We used 
chitosan as, chitosan is a naturally occurring mucoadhe-
sive polysaccharide having a strong affinity for Mucin-1 
receptor (Muc-1) expressing endothelial and epithelial 
cells [26]. Additionally, chitosan as a nanocomplex car-
rier equips the nanocomplex to undertake transcellu-
lar and paracellular internalization pathways and also 
exhibits strong affinity to cholesterol and triglycerides 
[27], and lipid accumulation is a primary characteristic of 
the atherosclerotic plaque inflammation [28]. Moreover, 
it has also been reported to accelerate the wound heal-
ing and exert anti-inflammatory effects [29]. Previously 
published studies have also shown that dietary chitosan 
inhibits hypercholesterolaemia and atherogenesis in the 
apolipoprotein E (apoE) deficient mouse model of ath-
erosclerosis [30]. Orally administered positively charged 
chitosan binds to lipids in the intestine, blocking absorp-
tion, shown to lower blood cholesterol in animals and 
humans as a result it has been proposed that dietary sup-
plementation with chitosan may inhibit the formation of 
atherosclerotic plaque [30]. Tail vein injection [31] and 
intranasal delivery [32] of chitosan based nanoformula-
tions have shown to successfully inhibit atherosclerosis 
in animal models. However, we were unable to synthesize 
optimum nanoparticles due to the large  polydispersity 
index (PDI). PEG on the other hand, also has several ben-
efits as it leads to formation of sterically stabilised ‘stealth’ 
particles [33] and its hydrophilic nature leads to reduced 
non-specific protein adsorption [34], avoids aggrega-
tion [35] and imparts the property of water solubility to 
the nanoparticles [36]. Therefore, we went on to replace 
chitosan with PEG and were able to synthesize optimum 
(224.8 nm, PDI 0.398) nanoparticles. A study performed 
to assess the distribution of Hsp-70 between fibrotic and 
necrotic plaques in immunostained carotid endarterec-
tomy specimens revealed that necrotic plaques and their 
underlying media contained significantly more Hsp-70 
expression than the fibrotic tissues [38]. Their results 
suggested that inadequate Hsp-70 accumulates with 
smooth muscle cells residing near necrosis to defend 
against plaque toxicity. Therefore, all nanocomplexes 
were conjugated with Hsp-70 for target specific internal-
isation. Hsp-70 is also known to protect cellular compo-
nents from injury by decreasing oxidation, inflammation 
and apoptosis and also by refolding damaged proteins 
[37].
Transmission electron microscopy (TEM) imaging 
confirmed the formation of all three spherical nano-
complexes (Fig.  1c, e, g). Lactoferrin ZF complex can 
be clearly observed by the TEM images. Furthermore, 
lactoferrin ZF complex embedded with chitosan can also 
be clearly observed by the TEM image. Intensity based 
hydrodynamic size distribution obtained by dynamic 
light scattering (DLS) exhibited an average diameter of 
224.8 and 275 nm for Hsp-70 Lf-PEG-ZF and Hsp-70 Ch-
Lf-ZF nanocomplexes respectively (Fig. 1e, g). A bimodal 
hydrodynamic size distribution was observed for Hsp-70 
Lf-ZF with the primary peak at 435.4 nm and secondary 
peak at 55.6  nm average diameter respectively (Fig.  1f ). 
Hsp-70 Lf-ZF and Hsp-70 Ch-Lf-ZF nanocomplex exhib-
ited a very high polydispersity index (PDI) value of 0.876 
and 0.865 respectively. Hsp-70 Lf-PEG-ZF exhibited a 
relatively narrow size distribution with a PDI value of 
0.398. Furthermore, lactoferrin loading was confirmed 
by band formation around 78 kDa for all nanocomplexes 
corresponding to lactoferrin as observed by poly acryl 
amide gel electrophoresis (PAGE) (Fig.  1i). The serum 
stability studies performed using DLS confirmed that 
Hsp-70 Lf-PEG-ZF showed least aggregation in 10  % 
bovine serum albumin (BSA), followed by Hsp-70 Lf-ZF 
and Hsp-70 Ch-Lf-ZF nanocomplexs (Additional file  1: 
Figure S1).
(See figure on previous page.) 
Fig. 1 Characterization of zinc doped ferrite nanoparticles and their nanocomplexes. a Transmission electron microscopy (TEM) image confirmed 
formation of uniformly sized spherical zinc-doped ferrite nanoparticles (Zn0.4Fe2.6O4) with an average diameter of 24 ± 2.8 nm. b X-ray differacto-
gram revealed the formation of crystallographic spinel structure of zinc-doped ferrite nanoparticles. c TEM image revealing the formation of Hsp-70 
Lf- ZF nanocomplex. d DLS analysis of Hsp-70 Lf-ZF nanoparticles revealed bimodal hydrodynamic size distribution with the prominent primary 
peak at 435.4 nm and a secondary peak at 55.6 nm with a polydispersity index of 0.876. e TEM image revealed the formation of Hsp-70 Ch-Lf-ZF 
nanocomplex. f DLS analysis revealed the hydrodynamic diameter of 275 nm with a PDI of 0.865. g TEM image revealing the formation of Hsp-70 
Lf-PEG-ZF nanocomplex and a highly magnified image (inset). h Dynamic light scattering (DLS) revealed the hydrodynamic diameter of 224.8 nm 
with a polydispersity index of 0.398. i Sodium dodecyl sulfate—polyacrylamide gel electrophoresis (SDS-PAGE) confirming lactoferrin loading of the 
nanocomplexes. From left to right, standard protein ladder, pure bovine lactoferrin (Lf ), ZF nanoparticles, Hsp-70 Lf-ZF, Hsp-70 Lf-PEG-ZF and Hsp-70 
Ch-Lf-ZF nanocomplexes. Nanocomplex lactoferrin loading was confirmed with specific band detection at 75 kDa
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Measurement of MRI/CT contrast and in vitro 
internalisation assessment of Hsp‑70 Lf‑PEG‑ZF 
nanoparticles
A slight enhancement of T1 MRI contrast (1.09-fold) 
was observed in Hsp-70 Lf-PEG-ZF compared to fer-
rite nanoparticles (Fig. 2a; Additional file 2: Figure S2a). 
Significant enhancement of T2 MRI contrast (p  <  0.05, 
1.22-fold) was observed in Hsp-70 Lf-PEG-ZF compared 
to ferrite nanoparticles (Fig. 2b, Additional file 2: Figure 
S2b). Slight enhancement of CT contrast (1.08-fold) was 
observed in Hsp-70 Lf-PEG-ZF compared to ferrite nan-
oparticles (Fig. 2c, Additional file 2: Figure S2c).
All three nanocomplexes were assessed with THP-1 
monocyte and T lymphocyte cell lines. The internali-
zation efficacy of these nanoparticles was tested using 
fluorescence confocal microscopy and flow cytometry 
(Fig.  2d, e). Confocal microscopy revealed very effec-
tive cellular internalization by all three nanocomplexes 
at 6  h after treatment with both cell lines. Flow cytom-
etry observation revealed that Hsp-70 Ch-Lf-ZF showed 
the maximum internalization in THP-1 cells (p < 0.001, 
1.41-fold higher than Hsp-70 PEG-Lf-ZF) whereas, Hsp-
70 PEG-Lf-ZF showed the maximum internalization in 
Jurkat cells (p  <  0.01, 2.05-fold higher than Hsp-70 Ch-
Lf-ZF). This is in accordance with previously published 
studies where mucoadhesive chitosan nanoparticles have 
been reported to internalize with very high efficiency in 
THP-1 cells without inducing any release of pro-inflam-
matory cytokines [39].
Monocytes and lymphocytes play central roles in ath-
erosclerotic inflammation from the early inflammatory 
phase to the late thrombotic phase [40]. Therefore, in this 
study, the nanocomplex effects and internalisation were 
studied with THP-1 monocytes and Jurkat lymphocytes 
as in vitro models of cells having a central role in athero-
sclerotic plaque inflammation [28].
Flow cytometry also revealed highly efficient inter-
nalization by monocytes as compared to lymphocytes 
primarily due to their Phagocytic characteristic. LDH 
release (cytotoxicity) and CyQUANT cell prolifera-
tion assays were performed in both THP-1 and Jurkat 
cells following treatment with all three nanocomplexes 
Fig. 2 Enhancement in MRI/CT contrast and internalisation efficacy of nanoparticles. a Slight enhancement of T1 MRI contrast was observed in 
Hsp-70 Lf-PEG-ZF compared to ferrite nanoparticles. b Significant enhancement of T2 MRI contrast was observed in Hsp-70 Lf-PEG-ZF compared to 
ferrite nanoparticles. c Slight enhancement of CT contrast was observed in Hsp-70 Lf-PEG-ZF compared to ferrite nanoparticles. d Confocal micros-
copy internalization images and cell cytometric internalization assessment displaying time-dependent internalization of Hsp-70 Lf-ZF, Hsp-70 Ch-Lf-
ZF and Hsp-70 Lf-PEG-ZF nanocomplexes in THP-1 cells and e Jurkat cells. Effective internalization was observed at 2 h Hsp-70 Lf-ZF nanocomplex 
post-treatment
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(Additional file  3: Figure S3a–c). The results revealed 
that Hsp-70 PEG-Lf-ZF failed to induce any significant 
cytotoxicity but led to a significant cellular proliferation 
(p < 0.05) with both THP-1 or Jurkat cells in lower con-
centrations (40–2.5 µg/ml). The Hsp-70 Ch-Lf-ZF led to 
significant cytotoxicity and significant reduction in pro-
liferation (p < 0.05) in both THP-1 and Jurkat at 100 µg/
ml and led to significant (p < 0.05) increase in prolifera-
tion in THP-1 cells at lower concentrations (50–2.5 µg/
ml).
Ex vivo MRI/CT of Hsp‑70 Lf‑PEG‑ZF nanoparticles in P. 
obesus atherosclerotic model
Psammomys obesus exhibit age-dependency and phe-
notypic heterogeneity in acquiring diabetes and obesity 
indicating the polygenic nature of pathogenesis in P. 
obesus, closely mimicking the human populations [41]. 
A genetic correlation between type-2 diabetes, athero-
sclerosis and inflammation has been well established 
since the discovery of the role of Tanis gene in P. obesus 
[22]. Since, we found that Hsp70-Lf-ZF was not suitable 
due to large particle size and Then we syntheized Hsp-
70 Ch-Lf-Zf nanocomplex had very high poydispersity 
index. Therefore, all further studies were conducted with 
Hsp70-PEG-Lf-ZF that has a narrower hydrodynamic 
size distribution.
Therefore, the next phase of ex  vivo imaging experi-
ments emulated a real-time in vivo scenario by injecting 
Hsp-70 Lf-PEG-ZF contrast agent directly into the intact 
animal aorta. Three groups of rats (18 months old Con-
trol n = 5, 6 months old injected with Hsp-70 Lf-PEG-ZF 
n = 5 and 16 months old injected with Hsp-70 Lf-PEG-
ZF n = 5) were used with minimal dissection steps prior 
to MRI/CT scan. Several benefits can be realized by using 
a direct intra-aortic ex vivo contrast agent injection strat-
egy. It imitates an in vivo MRI scan of the animal provid-
ing additional internal anatomical information from MRI 
contrast interferences arising from organs, tissues and 
other materials and fluids, especially fat. Furthermore, 
the strategy minimizes the risk of causing any damage 
to the aorta and heart prior to imaging. There is mini-
mal dissection, and pre-treatment electrocautery steps 
to seal aortic branches can be avoided with no possibility 
of any unwanted artefacts. The exploratory ex vivo MRI/
CT assessment reported in this study paves the way for 
future in vivo multi-modal imaging studies with P. obesus 
for development of atherosclerotic inflammation specific 
contrast or therapeutic agents.
Representative images (Fig.  3a) and the correspond-
ing heat map images (Additional file 4: Figure S4a) were 
presented for simplification. The control animal, per-
fused with PBS only showed minimal MRI intensity in 
all three orientations (Transverse, sagittal and coronal). 
High positive contrast exhibiting peri-aortic fat accumu-
lation was clearly observable around the arch region. The 
renal artery had a poorly defined periphery with the sag-
ittal scan images. Transverse scan images provided the 
most prominent information about the aortic peripheral 
morphology with the contrast agent injected in young 
and old animals. However, with the PBS injected animal 
the periphery was very poorly defined to derive any con-
clusion about P. obesus cardiovascular health status. A 
detailed examination of the aortic morphological status 
was conducted with the MRI assessment with both young 
(6 months old) and old (16 months old) direct Hsp-70 Lf-
PEG-ZF agent injected P. obesus. A higher overall aortic 
contrast intensity (p < 0.05, 1.71-fold) was observed in the 
old animals compared to the younger counterparts (Addi-
tional file 4: Figure S4b). However, both animals displayed 
atherosclerotic narrowing with intense T2 relaxed nega-
tive contrast at the descending aortic arch site adjacent 
to the high positive contrast peri-aortic fat accumulation. 
This mixed positive negative contrast at the arterial nar-
rowing sites is caused by negative MRI contrast signal 
arising from accumulated contrast agent and positive 
contrast exhibited by lipid at the atherosclerotic plaque 
site. The young animal MRI images exhibited moderate 
site-specific accumulation only at the aortic arch site with 
arterial stenosis and the remaining tissue. Alternatively, 
the older animal displayed strong contrast enhancement 
at the aortic arch and descending thoracic aorta regions 
and moderate contrast at the abdominal aorta.
MRI scan of the aorta from these rats exhibited mod-
erate contrast enhancement at the aortic arch and sig-
nificantly high contrast enhancement at the descending 
thoracic aorta region compared to the control. The 
nanocomplex contrast agent injected heart and aorta 
agar phantom was made in a customized diamagnetic 
holder to avoid any scan interference and imaging was 
performed with a 9.4T MRI scanner (Fig.  3b; Addi-
tional file  5: Figure S5). Overall, excellent T2 MRI con-
trast enhancement was observed with the contrast agent 
injected old animal aortas compared to the young animal 
aortas and the control.
Additionally, contrast agent injected 16  months old 
(adult) P. obesus were subjected to X-ray CT scan to 
assess aortic arch contrast agent localization corre-
sponding to the T2 MRI scan. Sagittal, transverse and 
coronal scan exhibited a clear streak with intense CT 
signal the aortic arch site due to targeted accumula-
tion (seen in white contrast) at the aortic arch site reaf-
firming the nanocomplex contrast agent accumulation 
at the aortic arch site (Fig.  4a–d). This was followed by 
CT imaging of the aorta to assess the potential for CT 
bimodality. The analysed aortic regions with T2 MRI 
contrast enhancement image directly corresponded with 
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the three dimensional  (3D) CT scan. The CT contrast 
enhancement at the aortic arch, thoracic aorta and iliac 
bifurcation region of the 16 month old animal precisely 
correlated with the MRI scan assessment, whereas the 
juvenile 6 month old animal did not exhibit any signifi-
cant CT contrast enhancement intensity relating to mod-
erately MRI contrast enhancement (Fig. 4e).
Site specific internalisation and biomarker analysis using 
histological studies
Histological analysis of aorta and heart tissues of Hsp-70 
Lf-PEG-ZF nanocomplex injected rats was performed 
and compared with control rats to visualize the contrast 
agent distribution and assess the severity of atheroscle-
rotic inflammation.
Fig. 3 T2 relaxation MRI scan imaging of Hsp-70 Lf-PEG-ZF nanocomplex contrast agent injected P. obesus aortae and hearts. a Six (n = 5) and 
16 months old (n = 5) rats were injected with Hsp-70 Lf-PEG-ZF nanocomplex contrast agent. Eighteen month old rats (n = 5) were maintained as 
control. Representative images were presented in transverse, sagittal and coronal orientation respectively. Red, yellow and white dotted lines outline 
the aorta, kidney and heart respectively. The spinal cord has also been pointed in white. The red arrows represent the atherosclerotic plaque site at 
the aortic arch region. b Shortlisted and magnified fat saturated T2 relaxation sagittal images showed high intensity site-specific MRI contrast that 
was attributed primarily due to disrupted aortic intimal structure possibly due to atherosclerotic pathological conditions like endothelial denuda-
tion, macrophages and foam cell entrapment, necrosis and calcification. High MRI contrast regions are indicated with red arrows
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Multiple cell types at the atherosclerotic aortic arch 
region including endothelial cells, smooth muscle cells 
and macrophages exhibited Hsp-70 overexpression 
(Fig. 5a). Aortic endothelium primarily expresses Hsp-70 
along with other intimal cells at atherosclerotic inflam-
matory sites in the atherosclerosis rat model (ApoE−/−), 
and a primate model (macaque) as well as humans (post-
mortem) [20, 42]. Complex atherosclerotic lesions were 
observed with foam cells and debris surrounded by extra-
cellular matrix and smooth muscle cells in the interlamel-
lar space. Stretch injured intima, endothelial denudation 
and loss of internal elastic lamina integrity was preva-
lent at the aortic arch region. Prevalent stretch induced 
intimal injury, endothelial denudation and loss of inter-
nal elastic lamina was observed throughout the aortic 
arch region. Cellular contrast agent internalization was 
observed with intimal migratory and non-migratory 
smooth muscle cells. Intimal macrophage accumulation 
at the aortic arch site also displayed significant contrast 
agent accumulation. Widespread endothelial denudation 
and disrupted elastic lamina was observed in at the aortic 
arch region. Disrupted endothelium, migrating smooth 
muscle cells and macrophages extensively expressed 
stress protein, mainly at the lumen and adventitial side of 
the intima. Smooth muscle cell migration and cell debris 
and apoptotic cells were observed all along the intimal 
region. Angiogenesis growth factor was mostly expressed 
by the intimal endothelium layer at the luminal side and 
migratory smooth muscle cells at the adventitial side of 
the intima. Longitudinally sectioned aortic arch displayed 
pathologically mature translational plaque protruding in 
the lumen with severe intimal thickening, lipid deposi-
tion, necrosis, fibrous cap formation and calcification.
The contrast agent injected adult animals exhibited 
severe intimal disruption and widening accompanied 
with collagen rich plaques with fatty streaks or intimal 
foam cell accumulation without necrosis along the entire 
length of the aorta. Luminal stenosis was accompanied 
by pathological intimal thickening with collagen rich 
xanthomas with early and late necrotic sites observed 
throughout the aorta, conditions predominantly respon-
sible for cerebral and myocardial infarction (Fig.  5b). 
Extensive lipid deposition was realized within the lumi-
nal plaque, intima and the necrotic core. Contrast agent 
exhibited selective accumulation at the occluded aortic 
arch region within the intima, necrotic core and adventi-
tia at the atherosclerotic inflammatory site validating the 
target-specific delivery of the developed Hsp-70 Lf-PEG-
ZF nanocomplex MRI contrast agent (Additional file  6: 
Figure S6).
The heart sections demonstrated highly conserved 
pericardium structure with contrast agent internali-
zation and no accumulation into the myocardium 
(Fig.  5c). Myocardial pericardium and aortic endothe-
lium exhibited nanoparticle internalization throughout 
the cardiovascular tissue, exhibiting an overall negative 
Fig. 4 X-ray computed tomography scan images of intra-aortic Hsp-
70 Lf-PEG-ZF contrast agent injected 16 month old P. obesus. a Sagit-
tal, b coronal, c transverse and d 3d reconstructed CT images. Red 
arrows indicate the streak at the aortic arch site with Hsp-70 Lf-PEG-
ZF nanocomplex accumulation. e Three dimensional reconstruction 
image generated with the Hsp-70 Lf-PEG-ZF nanocomplex injected P. 
obesus hearts and aortae agar phantom CT scan (inset). The periphery 
of the cardiovascular tissue was outlined with a dotted white line 
following a tissue outline observed with the CT image. Aortic regions 
with enhanced CT contrast are evident in the aorta and highlighted 
by red and blue dotted lines representing the aortic arch and terminal 
iliac bifurcation respectively
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T2 MRI contrast generating images of the entire struc-
ture. The aortic arch and descending thoracic aorta 
exhibited severe contrast agent accumulation across 
the intima and media into the adventitia, attributed pri-
marily to diffusion through atherosclerotic disrupted 
aortic intimal and medial structure. It should be noted 
that altered endothelium permeability, function and 
expression is accelerated by irregular hemodynamic 
flow at the sites of arterial bifurcation and curvature 
[43–45]. The contrast agent can therefore be targeted 
to the atherosclerotic inflammatory site by passive dif-
fusion through the damaged intima as well as active 
targeting by lactoferrin and Hsp-70 multi-cellular 
receptors (Fig. 6). Collagen-rich plaques with significant 
Fig. 5 Histological assessment images for nanoparticle distribution and vascular morphology assessment of intra-aortic Hsp-70 Lf-PEG-ZF nano-
complex contrast agent injected P. obesus aorta and heart sections. Nanoparticle distribution images of axially sectioned captured at ×20 magni-
fication and the tissues were and stained with Prussian blue iron stain and Pararosalinine cellular and nuclear stain. a Immunohistological images 
of axially sectioned aortic arch from control rats and Hsp-70 Lf-PEG-ZF injected rats, stained against Prussian blue iron stain, Hsp-70, CD44 and 
VEGF respectively captured at ×20 magnification. b Longitudinal section of aortic arch tissue arch from control rats and Hsp-70 Lf-PEG-ZF injected 
rats stained against hematoxylin nuclear and oil red-O lipid stain captured at ×10 magnification. Advanced atherosclerotic plaque causing severe 
luminal stenosis was observed at the aortic arch region. Pathological intimal thickening with significant lipid deposition within the intima, media, 
necrotic core as well as extracellular lipid accumulation in the aortic lumen was observed. c Nanoparticle accumulation could not be observed in 
the heart with no disruption of the pericardium. Aortic arch section displayed severely disrupted intimal structural integrity and widening of first 
interlamellar spaces with atherosclerotic micro lesions. The nanoparticles can be seen attached with the intimal endothelium, within the intima and 
across into the adventitia. Descending thoracic aorta with complex micro lesions displayed significant nanoparticle accumulation within the intima 
and adventitia. Intima widening could be observed with blue steaks in the intima indicating cellular internalization and interlamellar contrast agent 
accumulation. The iliac bifurcation section adjacent to the abdominal aorta with partly disrupted intimal integrity and fewer lesions was observed. 
The endothelial layer was mostly conserved with minimal endothelium denudation. Adventitial nanoparticulate contrast agent accumulation was 
also minimal abdominal aortic region. Number of micro-atherosclerotic lesions and intimal widening was significantly less in comparison to aortic 
arch and descending thoracic aorta. Hematoxylin, Methyl green and Pararosalinine were used for nuclear staining and antibodies were stained with 
3,3’-Diaminobenzidine DAB
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luminal stenosis were prevalent throughout the aorta. 
Healed erosions or ruptures led to large areas of calcifi-
cation with inflammatory cells and minimal or absence 
of necrosis. Stretch induced intimal injury, endothelial 
denudation, loss of elastic lamina, smooth muscle cell 
migration, macrophage and apoptotic cell accumulation 
were clearly visible at the complex aortic arch micro-
angiogenesis region.
Fig. 6 Schematic representation of different mechanisms of passive and targeted nanocomplex delivery and cellular internalization at the athero-
sclerotic inflammatory region. The diagram schematically represents targeted and passive delivery and cellular interaction of nanocomplexes (Hsp-
70 Lf-ZF, Hsp-70 Lf-PEG-ZF and Hsp-70 Ch-Lf-ZF) at the site of atherosclerotic inflammation. The nanocomplexes in the luminal hydrodynamic flow 
have been shown to enter the intimal layer due at the plaque site due to endothelial denudation or leaky vasculature. The Ch-Lf-ZF nanocomplex 
has been represented to cross the intimal endothelial layer by paracellular and transcellular pathways and also interacting with the mucin recep-
tors followed by internalization. The cells under stress at the plaque sites exhibit cytoprotective Hsp-70 overexpression and therefore the Hsp-70 
targeted nanocomplexes have been shown to interact with multiple cell types followed by internalization. Lactoferrin mediated cellular interac-
tion and receptor-mediated (TfR, TfR1, TfR2, LfR, LRP, LRP1) internalization has been shown with a representative macrophage cell (enlarged). Also, 
Lactoferrin potentially interacts with the macrophage scavenger receptor saturating further lipoprotein uptake by the macrophages and preventing 
further inflammation. The nanoparticles also exhibiting endocytosis and pinocytosis has also been represented. The nanocomplexes finally break-
down and the zinc ferrite nanoparticles released within the cells
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Conclusion
The study demonstrated development of engineered ath-
erosclerosis targeted ZF nanoparticle nanocomplex based 
T2 relaxation MRI contrast agent which was validated 
in an ex  vivo setting. We also observed that lactoferrin 
receptor and Hsp-70 antibody induced atherosclerotic 
inflammatory site specific multi-cellular targeting. Addi-
tional insight about aortic contrast agent distribution, 
accumulation, targeting and internalization was gained 
by histological examination with both longitudinally and 
axially oriented aorta and heart sections of contrast agent 
injected P. obesus rat. Particularly, likely disruptions in 
the aortic intimal structure due to hemodynamic stress 
around bifurcation sites were identified, especially in 
the aorta, a characteristic feature of atherogenesis lead-
ing to leaky vasculature. The direct intra-aortic contrast 
agent injection strategy effectively avoids any artefacts 
and negates the risk of any damage to the aorta. Juvenile 
P. obesus (6 months old) aorta and heart images present a 
significantly lower overall T2 MRI contrast enhancement 
in comparison to the adult animals (16  months old), 
attributed to more conserved and intact intimal endothe-
lium structure. The adult P. obesus aorta and heart MRI 
images displayed high overall T2 negative contrast. Sig-
nificant site-specific T2 MRI contrast was observed at 
the aortic arch, abdominal thoracic aorta and iliac bifur-
cation region indicating increasingly disrupted aortic 
peripheral structure and multi-molecular cellular target-
ing at these sites. The CT image verified site-specific con-
trast enhancement observed by aortic T2 MRI scans of 
16 month old P. obesus where a significant contrast was 
observed at the aortic arch, thoracic aorta and iliac bifur-
cation. The point to be noted here is that not the entire 
contrast enhancement observed by MRI was reflected 
in the CT scan. Therefore, the CT contrast is generated 
only at the specific sites with significant contrast agent 
accumulation, requiring a high concentration to produce 
effective CT contrast. Accumulation of MRI contrast 
agent at atherosclerosis inflammation prone sites, spe-
cifically the aortic arch, descending thoracic aorta and 
iliac bifurcation in adult P. obesus, was reaffirmed by the 
3D reconstructed CT image. MRI contrast generation is 
an intricate process and requires manipulation of sev-
eral parameters in order to produce contrast depending 
on the proton spin of the material under external mag-
netic fields. On the other hand, X-ray CT is quite straight 
forward and is based on electron density of the mate-
rial. On striking the material the X-rays pass through 
low electron density material with no loss of intensity as 
observed by a receiving detector. When the electron den-
sity is sufficiently high due to contrast agent accumula-
tion, the X-ray shows a change in intensity at the receiver 
registered as contrast. In the case of Hsp-70 Lf-PEG-ZF 
injected cardiovascular tissue of 16  month old rats, the 
CT contrast enhancement was noted at various sites due 
to contrast agent accumulation. As mentioned earlier, the 
contrast agent accumulation at these sites could be due to 
several factors, primarily disruption in the aortic intima 
leading to a leaky vasculature, targeted and passive nano-
particle internalization. The factors leading to accumula-
tion at specific aortic sites was successfully evaluated by 
thorough histological analysis. Site-specific T2 relaxation 
signal intensity exhibiting contrast agent would require 
considerably reduced administrative dose for highly 
effective diagnosis of atherosclerosis. This is the first ever 
study reporting enhanced ex  vivo bimodal CT contrast 
with zinc-doped ferrite nanoparticle nanoparticles based 
MRI contrast agent identifying unexplored new avenues 
in cardiovascular imaging research. Ex vivo CT/MRI 
contrast enhancement using Hsp-70 Lf-PEG-ZF contrast 
agent showed promising results opening multimodal 
applicability avenues for ferrite nanoparticle based con-
trast enhancement.
The imaging experiments reported in this study imi-
tated a real-time in  vivo scenario by injecting Hsp-70 
Lf-PEG-ZF contrast agent directly into the intact ani-
mal aortas with minimal dissection steps prior to MRI/
CT scan. Several benefits can be realized by using direct 
intra-aortic ex  vivo contrast agent injection strategy. It 
imitates an in  vivo MRI scan of the animals providing 
additional internal anatomical information from MRI 
contrast interferences arising from organs, tissues and 
other materials and fluids, especially fat. The contrast 
agent validation and atherosclerosis-specific targeting 
in this study justifies further studies in order to strate-
gically observe the contrast agent in in  vivo scenarios. 
Furthermore, the strategy minimizes the risk of causing 
any damage to the aorta and heart prior to imaging. The 
exploratory ex  vivo MRI/CT assessment reported here 
paves way for future in vivo multi-modal imaging studies 
with P. obesus for development of atherosclerotic inflam-
mation specific contrast agents with potential for therapy.
Methods
Synthesis of zinc ferrite (ZF) nanoparticles
An optimized batch of ZF nanoparticles Zn0.4Fe2.6O4 
was synthesized using a hydrothermal chemical synthe-
sis technique. Laboratory reagent grade ferric chloride 
(FeCl3·6H2O), ferrous chloride (FeCl2·4H2O), zinc chlo-
ride (ZnCl2) and analytical reagent grade sodium hydrox-
ide (NaOH) were purchased from Ajax Fine Chemicals 
(Australia). FeCl3·6H2O 0.125 M was dissolved with cal-
culated amounts of 0.125  M FeCl2·4H2O and 0.125  M 
ZnCl2 in de-oxygenated and de-ionised water to obtain 
an aqueous solution with Fe3+, Fe2+ and Zn2+ ions 
respectively. The solution was stirred at 200  rpm and 
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maintained at room temperature followed by drop wise 
addition of 1  M NaOH reducing agent. The suspension 
was immediately autoclaved for annealing at 150  °C for 
12  h. The precipitated zinc doped ferrite nanoparticles 
were washed multiple times by magnetic decantation. 
Subsequently, the nanoparticles were freeze dried at 
−80 °C and 0.013 mbar pressure for 24 h.
Synthesis of nanocomplexes
For the synthesis of Hsp-70 Lf-ZF nanocomplex, 20 mg 
of optimized ZF nanoparticles were dispersed in 10  ml 
deionised water and ultrasonicated at high intensity for 
30 min. Dopamine, 2 mg/ml (Sigma Aldrich) was added 
to the nanoparticle aqueous suspension and ultrasoni-
cation was continued for another 30  min. The particles 
were washed by magnetic decantation and redispersed 
in 10  ml water and stirred at 200  rpm at 4  °C. 2.7  ml 
1-Ethyl-3-(3-di-methylaminopropyl) carbodiimide (EDC) 
(2 mg/ml) (Sigma Aldrich) was added to the nanoparti-
cle suspension followed by addition of 3.4 ml N-hydrox-
ysulfosuccinimide (NHS) (Sigma Aldrich) (2  mg/ml) at 
45  min and the aqueous suspension was allowed to stir 
overnight at 4  °C (EDC/NHS coupling). The unreacted 
coupling agents were removed by magnetic decanta-
tion followed by addition of 5 mg/ml bovine lactoferrin 
solution to the activated nanoparticles with continuous 
stirring for 12 h. The nanocomplex was collected by cen-
trifugation at 5000 rpm for 30 min. Lactoferrin zinc fer-
rite (Lf-ZF) nanocomplexes were redispersed in milliQ 
water and reactivated by EDC/NHS coupling reaction 
(Additional file 7: Figure S7). The reaction was quenched 
by adding 10 µl β-mercaptoethanol followed by addition 
of 10 ml heat shock protein antibody (Hsp-70) (Sapphire 
Biosciences) in water (1:1000) and stirred at 200 rpm at 
4  °C for 12  h. The final antibody nanoparticle complex 
was recovered by centrifugation at 5000 rpm for 30 min 
and freeze dried at −80 °C and 0.013 mbar pressure. Hsp-
70 Lf-ZF nanoparticle sample was obtained in powder 
form and used for further characterization and experi-
ments. Synthesis of Hsp-70 Lf-PEG-ZF involved disper-
sion of 200 mg ZF nanoparticles in ultrapure water and 
ultrasonication for 30  min. This was followed by addi-
tion of 200  mg carboxylated polyethylene glycol (PEG) 
(molecular weight 1000) (JenKem, USA) and ultrasoni-
cation was continued for 30 min at 80 % amplitude. The 
particles were washed by magnetic decantation and 
redispersed in 10 ml water and stirred at 200 rpm at 4 °C. 
2.7 ml EDC (2 mg/ml) (Sigma Aldrich) was added to the 
nanoparticle suspension followed by 3.4 ml NHS (2 mg/
ml) after 45 min and the aqueous suspension was allowed 
to stir overnight at 4  °C. The unreacted coupling agents 
were removed by magnetic decantation followed by addi-
tion of 10  ml aqueous solution containing 5  mg bovine 
lactoferrin. After 12  h, the nanocomplex was collected 
by centrifugation at 5000 rpm for 30 min. The nanopar-
ticles were redispersed in 10 ml water followed by EDC/
NHS coupling and 50  µl β-mercaptoethanol followed 
by addition of 10  ml Hsp-70 antibody in water (1:1000) 
and stirred at 200 rpm at 4 °C for 12 h (Additional file 8: 
Figure S8). The nanocomplex was recovered by centrif-
ugation at 5000  rpm for 30  min and the pellet was fro-
zen in liquid nitrogen and freeze dried at −80  °C and 
0.013 mbar pressure. The chemical reaction and synthesis 
steps have been schematically described in supplemen-
tary information. For the synthesis of Hsp-70 Ch-Lf-ZF 
nanocomplex, 40 mg ZF nanoparticles were dispersed in 
10 ml ultrapure milliQ water and ultrasonicated at high 
intensity for 30  min. Ultrasonication was continued for 
another 30 min in 10 ml of 2 mg/ml aqueous dopamine 
solution. The nanoparticles were washed by magnetic 
decantation and redispersed in 10 ml milliQ water. 2.7 ml 
of 2 mg/ml EDC (Sigma Aldrich) was added to the nano-
particle suspension followed by addition of 3.4 ml 2 mg/
ml NHS (Sigma Aldrich) (2  mg/ml) to initiate the cou-
pling reaction stabilizing the amine reactive intermedi-
ate at 45 min and the aqueous suspension was allowed to 
stir overnight at 4 °C. The nanoparticles were recollected 
by centrifugation at 5000g for 30  min and redispersed 
in 90  ml water with 200  mg chitosan. The solution was 
stirred and maintained at 4  °C with constant stirring at 
200 g. 10 ml of 2 mg/ml Sodium tri-polyphosphate solu-
tion in acetate buffer was added to the working solution 
drop wise and the solution was allowed to stir for 2  h. 
The solution was centrifuged at 5000g for 30 min and the 
pellet was collected and redispersed in 10 ml water fol-
lowed by EDC/NHS activation and the coupling reaction 
followed quenching using 10μl β-mercaptoethanol. 10 ml 
of 1:1000 Hsp-70 antibody was added drop wise to the 
solution and stirred overnight. The nanocomplex solu-
tion was washed twice and collected by centrifugation at 
5000 rpm for 10 min. Finally the nanocomplex was freeze 
dried at −80 °C and 0.013 mbar pressure. All nanocom-
plexes were stored at 4 °C temperature.
Characterization procedure for nanoparticles
TEM assessment of nanoparticle and nanocomplex char-
acterization was performed with JEOL JEM-2100® LaB6 
transmission electron microscope. All samples were 
prepared on carbon coated 400 mesh GSCU400C-50 
Formvar® Copper grids and simultaneous sequentially 
imaging was performed. Standard operating protocol 
was followed with constant 200  kV high tension volt-
age and 110  µA beam current. Hydrodynamic size and 
zeta potential measurements were performed with Mal-
vern Zetasizer Nano® ZS. Crystallographic assessment 
was performed with Panalytical X’Pert® PRO X-ray 
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diffractometer. Freeze dried nanoparticle powder was 
placed in the sample holder and the top surface layer 
was smoothened. The scans were performed from 10° 
to 70° 2θ X-ray beam angle with 0.02 unit step size per 
2  s. For PAGE, equal amounts of protein and lactofer-
rin nanocomplex (with 5× loading dye) were subjected 
to Sodium Dodecyl Sulfate-Poly acrylamide gel Elec-
trophoresis (200 V, 3A, 300 W) on 10 % gel to visualize 
the bands. Polyacrylamide gel contained 1.5 M (pH 8.8) 
and 1  M (pH 6.8) Tris buffer (Sigma Aldrich) for sepa-
rating and stacking gel respectively, 30  % Acrylamide 
(Bio-Rad), 10  % Ammonium Persulfate (APS) (Bio-Rad) 
and 0.2 % TEMED (Sigma Aldrich). The gel was treated 
with Coomassie staining solution for 1  h followed by 
de-staining solution treatment for 30  min. The gel was 
imaged using Bio-rad Chemidoc XRS and the bands were 
assessed.
The nanocomplexes were dissolved in 10  % BSA in a 
concentration of 1  mg/ml until a period of 7  days and 
accumulation in the respective nanocomplexes was 
observed using DLS at regular time intervals. The T1, T2 
and CT contrast of the Hsp-70 Lf-PEG-ZF nanocomplex 
was compared with commercially available ferrite nano-
particles. Equal weight of both nanoparticles was set in 
1 % agar in a customized diamagnetic sample holder for 
nominal magnetic resonance response and the contrast 
was observed. The MRI was performed at the Monash 
biomedical imaging centre, Melbourne. The Agilent 9.4 
T MRI small animal scanner was used for this study. 
This instrument is equipped with 1H 63/108  mm coil 
designed as a standard 16-element coil with 6 cm sample 
diameter, which is suitable for small animal imaging. The 
T1 and T2 MRI signal intensities of nanoparticles were 
measured and analysed using the Vnmr J4 software. The 
CT scans were obtained using the SOMATOM CT scan-
ner (Siemens Australia) also at the Monash Biomedical 
Imaging Centre, Melbourne.
In vitro methodologies used
Human THP-1 monocytes (ATCC® TIB-202™) and Jur-
kat T-lymphocytes Clone E6-1 (ATCC® TIB-152™) cell 
lines were obtained from American type culture collec-
tion (ATCC), Virginia, United States of America (USA). 
Both cell lines were grown in Roswell Park Memorial 
Institute (RPMI) 1640 media supplemented with Dul-
becco’s Modified Eagle Medium (DMEM) obtained from 
Gibco™ Life Technologies (Australia) and 1 % penicillin/
streptomycin (P/S). The cells were maintained at 37  °C 
and 5 % CO2 in a humidified incubator (Heracell® 150i, 
Thermo Scientific, Australia). The cells were regularly 
subcultured in 25 and 75  cm2 cell culture flasks pur-
chased from Greiner BioOne™ (Australia) after attain-
ing 80–90  % confluence. Being non-adherent cell lines, 
the suspension cells were directly collected and centri-
fuged at 1200  rpm for 5  min. After centrifugation, the 
cell viability was estimated by trypan blue haemocytom-
eter count using a microscope and 1 × 105 cells/ml were 
resuspended in flasks with fresh media.
Cytotoxicity studies using lactate dehydrogenase (LDH) 
assay
The cytotoxic effects nanocomplexes were assessed by 
lactate dehydrogenase (LDH) detection assay kit (Roche, 
Australia) according to the manufacturer’s instructions. 
Cells were incubated in 96 well plates at a cell density 
of 1x105cells/ml and incubated for 24–48  h at 37  °C in 
a humidified 5  % CO2 atmosphere. Post-incubation the 
cells were incubated with all the treatments prepared 
in 1  % serum supplemented RPMI medium. The cells 
were then incubated at 37 °C for 24 h. Controls were set 
up as per the manufacturer’s instructions, with a posi-
tive control using 100  µl cells with 10  % serum supple-
mented media, 100 µl 1 % Triton-X 100 (Sigma Aldrich, 
Australia) as negative control and treatments containing 
100 µl of cells grown in 1 % serum supplemented media. 
After incubation the plate was centrifuged at 4800  rpm 
for 5  min at room temperature to settle the cells and 
debris. The supernatant from each well was then col-
lected and transferred to a fresh 96 well plate. To this 
supernatant, freshly prepared 100  µl of standard LDH 
reaction solution was added and the plate was incubated 
in the dark for 30 min at room temperature. After incu-
bation the absorbance was measured using a micro plate 
reader (Corona electric) using a filter of 492  nm with a 
reference of 620 nm.
Cell proliferation studies using CyQUANT assay kit
Cell proliferation studies were also conducted using 
the CyQUANT cell proliferation kit (Life Technolo-
gies, Australia) which is a colorimetric based detec-
tion method for assessment of proliferating cells as the 
GR dye component binds directly to the DNA of pro-
liferating cells. The cells were cultured at a cell density 
of 1  ×  105  cells/ml in a 96 well plate. The cells were 
allowed to grow at 37 °C at 5 % CO2 for 48 h. The plates 
were centrifuged at 1500  rpm and the media was dis-
carded. Cells were treated for 24  h and all treatments 
were prepared in 1  % serum supplemented media. 
The incubation was done at 37  °C and 5  % CO2. Con-
trols were maintained with only media and one group 
was incubated with 20  % serum supplemented media 
to achieve maximum proliferation acting as a positive 
control. After incubation for 24  h, the 96 well plates 
were centrifuged at 1200g for 5  min. The supernatant 
was carefully discarded and the cells were then air-
dried for 30  min. After drying the plate was covered 
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in aluminium foil and stored at −80  °C. The plate was 
removed from −80  °C storage after 48 h and 200 µl of 
the standard reaction solution was added and fluores-
cence was measured at excitation/emission wavelength 
of 485/530 nm using a microplate reader.
Nanoparticle internalization studies using confocal 
and flow cytometry
For internalization assessment, cells were cultured in 
six well plates at an estimated population of around 
2  ×  105  cells/ml for 24  h. Cells were time-depend-
ently treated with 2g/ml Rhodamine labelled 100  µg/
ml nanocomplexes in 1  %  FBS RPMI-1640 media. 
Nanocomplex Rhodamine (Sigma) labelling was per-
formed using standard EDC/NHS coupling reaction. 
The nanocomplex treated cells were centrifuged at 
1200 rpm for 5 min and the pellet was redispersed in 
1  ml PBS. The cell populations were sorted for nano-
complex internalization using fluorescence assisted 
cell sorter and nanocomplex untreated cells were used 
as control cell population. Confocal microscopy was 
performed with cells cultured in six well plates at an 
estimated 2 ×  105 cells/ml population. The cell treat-
ments including controls including untreated control 
were centrifuged (1200  rpm, 5  min). The resulting 
pallet was redispersed in 200  µl PBS and slides were 
prepared for confocal fluorescence microscopy using 
the CytoSpin™ cell centrifugation system (1600  rpm, 
6  min). The cell layer on the slide was allowed to air 
dry for 1  h, treated with DAPI mounting media and 
a coverslip is placed on top avoiding air bubbles. The 
coverslip was sealed on top of slide and observed 
under confocal microscope.
Ex vivo assessment for validation of MRI and CT contrast 
of Hsp‑70 Lf‑PEG‑ZF nanocomplex
Psammomys obesus was used as a model for valida-
tion of Hsp-70 Lf-PEG-ZF nanocomplex MRI contrast 
agent, ex  vivo. The rat colony was maintained at the 
animal housing facility, Deakin University (Geelong, 
Australia). Breeding pairs were fed a standard rodent 
laboratory diet (Barastoc®, Pakenham, Australia). The 
animals were weaned at 4 weeks of age and switched 
to a standard laboratory diet, from which 12  % of 
energy was derived from fats, 63  % from carbohy-
drates, and 25 % from proteins. Animals were housed 
in a temperature-controlled room (22 ±  1  °C) with a 
12 h light–dark cycle (light 0600–1800 h). The experi-
mental samples for MRI and CT scans were prepared 
with two different strategies: extracted aorta and 
heart nanocomplex injected agar phantom and direct 
nanocomplex injection in the animal aorta post-
sacrifice. For ex  vivo assessment, juvenile [6  months 
old (n =  5)] and adult [16 (n =  5) and 18  month old 
(n  =  5)] animals were humanely sacrificed in a CO2 
chamber. Blood clotting within the cardiovascular 
vessel was prevented by promptly exposing the aorta 
followed by PBS perfusion immediately post-sacri-
fice. Any damage or dislocation of internal organs 
was minimized while exposing the aorta to keep the 
original structure intact. Nanocomplex contrast agent 
injection was followed right after PBS perfusion at the 
iliac bifurcation to prevent any blood clot formation in 
the aorta. Equal concentration of blood was removed 
prior to PBS perfusion and contrast agent injec-
tion. Young 6 month (n = 5) and adult 16 month old 
animals (n  =  5) served as contrast agent treatments 
(100  µg/ml Hsp-70 Lf-PEG-ZF) and the 18  month 
old adults (n =  5) served as a control for MRI/com-
puted tomography (CT) assessment. Animal thorax 
was sealed back and imaging was performed with all 
animals after 4 h of treatment. Scans were performed 
in coronal, sagittal and transverse orientation in order 
to have a three dimensional observation assessment of 
the atherosclerosis plaque sites. Constant scan param-
eters were maintained at 6.25  ms gradient echo (TE) 
and 8000  ms repetition time (TR) with fat saturation 
for all scans performed.
Later, the thorax and abdomen were rinsed with 
70  % ethanol, an incision was made using sterile scis-
sors and toothed forceps and the skin was removed. 
The thorax was opened exposing heart, lungs and the 
abdomen and the organs were carefully dissected and 
removed. Electrocautery was performed at all branches 
to remove the entire aorta and heart, simultaneously 
sealing all the vessel branches. The aorta was dissected 
below the iliac bifurcation using sterile micro-dissect-
ing scissors. Intact aortae and hearts were moved to a 
petridish containing phosphate buffered saline (PBS) 
and PBS perfusion was performed at the iliac bifur-
cation end to remove any blood. The peri-aortic fat 
was meticulously removed preventing any damage to 
the blood vessel. The nanocomplex suspension was 
removed after 6 h of treatment and perfused with PBS 
to remove any unbound nanocomplex from the luminal 
aortic region. Finally, the tissues were fixed at 4 °C using 
4 % Paraformaldehyde and set in 1 % agar in a custom-
ized diamagnetic sample holder for nominal magnetic 
resonance response. Nanocomplex injected aortae and 
hearts agar phantom were observed with the MRI and 
X-ray CT scanner.
Histological analysis of plaque, nanocomplex binding 
and biomarkers
In order to detect the sites of atherosclerotic lesion/
fatty streaks detected by MRI/CT imaging, the 
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vasculature was divided into four parts: heart, aortic 
arch, descending aorta and abdominal aorta. 10  µm 
thick longitudinal and axial tissue sections were 
obtained using a cryotome on poly-lysine coated 
microscopic slides. The sections were fixed with 
acetone at −20  °C for 15 min. Standard protocol was 
followed to stain the sections with haematoxylin and 
eosin (H&E), methyl green and oil red-O to visualise 
the structure of cells and lesions/streaks in the aor-
tic intima. For H&E staining the tissue sections were 
stained with haemotoxylin for 8  min and washed 
with tap water. Counterstaining was done with eosin 
for 2  min and the tissue was washed again with tap 
water. The tissue was subjected to acid alcohol for 
2 s and washed gently with tap water. The slides were 
rehydrated/dehydrated in 70, 90 and 100  % ethanol 
sequentially for 2 min each. The sections were allowed 
to air dry and mounting media was added followed by 
placement of a coverslip avoiding any bubble forma-
tion. Standard manufacturer’s staining protocol was 
followed to stain the tissue sections with Prussian 
blue iron stain and Pararosalinine cellular staining kit 
(Sigma Aldrich) to observe nanoparticle targeting and 
localization. Immunohistological analysis was per-
formed with 3,3′-Diaminobenzidine (DAB) staining 
against macrophage-specific CD44, Vascular endothe-
lial growth factor (VEGF) and stress protein Hsp-70 
for atherosclerosis plaque characterization. For DAB 
staining, the tissues were surrounded with a hydro-
phobic barrier using a barrier pen. To quench endoge-
nous peroxidase activity, samples were incubated with 
1-3 drops of peroxidase blocking reagent (3 % H2O2 in 
water or methanol) for 5–15  min. The samples were 
rinsed and gently washed in wash buffer for 5  min. 
To reduce non-specific hydrophobic interactions 
between the primary antibodies and the tissue, the 
sections were blocked with 1–3 drops of 3  % bovine 
serum albumin for 15  min. The slides were drained 
and any excess blocking reagent removed before pro-
ceeding to the next steps. The samples were incu-
bated with primary antibodies with incubation buffer 
at 37  °C for 1  h or overnight at 4  °C. Manufacturer’s 
recommendations were followed regarding working 
dilution for the primary antibody. The samples were 
washed 3 times with wash buffer for 5 min each, and 
drained, then incubated with secondary antibody at 
37 °C for 1 h. DAB reagent was then added and incu-
bated for 5–10  min. The nucleus was counterstained 
either with methyl green or haematoxylin. The tissues 
were fixed with mounting media and a coverslip was 
placed avoiding any bubbles. Finally, the slides were 
observed under light microscope and images were 
captured.
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in the T2 contrast was observed in Hsp-70 Lf-PEG-ZF nanoparticles when 
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